{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:02:29Z","timestamp":1782842549611,"version":"3.54.5"},"reference-count":31,"publisher":"JMIR Publications Inc.","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Internet Res"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Researchers face challenges in patient recruitment, especially for rare, fatal diseases such as amyotrophic lateral sclerosis (ALS). These challenges include obtaining sufficient statistical power as well as meeting eligibility requirements such as age, sex, and study proximity. Similarly, persons with ALS (PALS) face difficulty finding and enrolling in research studies for which they are eligible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to describe how the federal Agency for Toxic Substances and Disease Registry\u2019s (ATSDR) National ALS Registry is linking PALS to scientists who are conducting research, clinical trials, and epidemiological studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Through the Registry\u2019s online research notification mechanism (RNM), PALS can elect to be notified about new research opportunities. This mechanism allows researchers to upload a standardized application outlining their study design and objectives, and proof of Institutional Review Board approval. If the application is approved, ATSDR queries the Registry for PALS meeting the study\u2019s specific eligibility criteria, and then distributes the researcher\u2019s study material and contact information to PALS via email. PALS then need to contact the researcher directly to take part in any research. Such an approach allows ATSDR to protect the confidentiality of Registry enrollees.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2013 to 2019, a total of 46 institutions around the United States and abroad have leveraged this tool and over 600,000 emails have been sent, resulting in over 2000 patients conservatively recruited for clinical trials and epidemiological studies. Patients between the ages of 60 and 69 had the highest level of participation, whereas those between the ages of 18 and 39 and aged over 80 had the lowest. More males participated (4170\/7030, 59.32%) than females (2860\/7030, 40.68%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The National ALS Registry\u2019s RNM benefits PALS by connecting them to appropriate ALS research. Simultaneously, the system benefits researchers by expediting recruitment, increasing sample size, and efficiently identifying PALS meeting specific eligibility requirements. As more researchers learn about and use this mechanism, both PALS and researchers can hasten research and expand trial options for PALS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2196\/28021","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T09:38:50Z","timestamp":1632303530000},"page":"e28021","source":"Crossref","is-referenced-by-count":10,"title":["Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry\u2019s Research Notification Mechanism"],"prefix":"10.2196","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0796-8861","authenticated-orcid":false,"given":"Paul","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5594-6931","authenticated-orcid":false,"given":"Jaime","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2246-3618","authenticated-orcid":false,"given":"Moon Kwon","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4719-4829","authenticated-orcid":false,"given":"Theodore","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0898-6081","authenticated-orcid":false,"given":"James D","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0505-1168","authenticated-orcid":false,"given":"Sabrina","family":"Paganoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6259-8923","authenticated-orcid":false,"given":"Hiroshi","family":"Mitsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4666-7495","authenticated-orcid":false,"given":"Richard Stanley","family":"Bedlack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6214-6687","authenticated-orcid":false,"given":"D Kevin","family":"Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159\/000351153"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6746a1"},{"key":"ref3","author":"Mitsumoto, H","year":"1998","journal-title":"Amyotrophic Lateral Sclerosis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880180711"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2018.54.6.2828189"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30091-7"},{"key":"ref7","unstructured":"ALS Registry Act Public Law20082021-01-01https:\/\/www.cdc.gov\/als\/ALSRegistryActPublicLaw.html"},{"issue":"7","key":"ref8","first-page":"1","volume":"63","author":"Mehta, P","year":"2014","journal-title":"MMWR Suppl"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0b013e3182a823e0"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2017.00068"},{"key":"ref11","unstructured":"ALS AssociationVA Provides Benefits to Veterans with ALS and Families20202021-01-01http:\/\/web.alsa.org\/site\/PageServer?pagename=va_provides_benefits.?"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2017.1406953"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/17482960802195913"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3109\/17482968.2010.484494"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00521"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24421"},{"key":"ref17","unstructured":"Centers for Disease Control and PreventionNational ALS Registry20202021-01-01https:\/\/www.cdc.gov\/als\/"},{"key":"ref18","unstructured":"Centers for Disease Control and PreventionALS Research Notification for Clinical Trials and Studies2021-01-01https:\/\/www.cdc.gov\/als\/ALSResearchNotificationClinicalTrialsStudies_Active.html"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/1753-6405.12868"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006855"},{"key":"ref21","unstructured":"New Eligibility Criteria Needed for ALS Clinical Trials201901312021-01-01https:\/\/www.neurologylive.com\/view\/new-eligibility-criteria-needed-for-als-clinical-trials"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26921"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-00336-9"},{"key":"ref24","unstructured":"SullivanThomasA Tough Road: Cost To Develop One New Drug Is $2.6 Billion; Approval Rate for Drugs Entering Clinical Development is Less Than 12%201903212021-01-01https:\/\/www.policymed.com\/2014\/12\/a-tough-road-cost-to-develop-one-new-drug-is-26-billion-approval-rate-for-drugs-entering-clinical-de.html"},{"key":"ref25","unstructured":"PateriaDineshSinghRahulPatients Recruitment Forecast in Clinical TrialsCognizant 20-20 Insights2015082021-01-01Teaneck, NJCognizanthttps:\/\/www.cognizant.com\/whitepapers\/patients-recruitment-forecast-in-clinical-trials-codex1382.pdf"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d3662"},{"key":"ref27","unstructured":"Massachusetts General HospitalHealey ALS Platform Trial2021-01-01https:\/\/www.massgeneral.org\/neurology\/als\/research\/platform-trial"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.ss6508a1"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000008620"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27091"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2014.12.012"}],"container-title":["Journal of Medical Internet Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jmir.org\/2021\/12\/e28021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:40:45Z","timestamp":1782841245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmir.org\/2021\/12\/e28021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2196\/28021","relation":{"has-preprint":[{"id-type":"doi","id":"10.2196\/preprints.28021","asserted-by":"object"}]},"ISSN":["1438-8871"],"issn-type":[{"value":"1438-8871","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,7]]}}}